Churg-Strauss syndrome associated with omalizumab.
Reports have suggested that the leukotriene receptor antagonists may cause Churg-Strauss syndrome following the tapering of oral corticosteroids or even in patients not treated with corticosteroids. We report a patient not treated with long-term corticosteroids and who developed Churg-Strauss syndrome with myocarditis and central nervous system involvement following the initiation of omalizumab. Given the possible role of omalizumab in the development of this vasculitis in our patient, we recommend careful monitoring of the appearance of Churg-Strauss symptoms and rising eosinophil count in patients treated with omalizumab.
Puéchal
Xavier
X
Department of Rheumatology, Le Mans General Hospital, 194 avenue Rubillard, 72000 Le Mans, France. xpuechal@ch-lemans.fr
Rivereau
Philippe
P
Vinchon
François
F
D000368:Aged; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002545:Brain Ischemia / Q000150:complications; D015267:Churg-Strauss Syndrome / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D004452:Echocardiography; D004804:Eosinophils / Q000378:metabolism; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009205:Myocarditis / Q000150:complications; D000069444:Omalizumab
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab